Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials

Background: It is imperative to identify drugs that allow treating symptoms of severe COVID-19. Respiratory failure is the main cause of death in severe COVID-19 patients, and the host inflammatory response at the lungs remains poorly understood. Methods: Therefore, we retrieved data from post-morte...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Cortés, Andrés, Guerrero, Santiago, Ortiz-Prado, Esteban, Yumiceba, Verónica, Vera-Guapi, Antonella, León Cáceres, Ángela, Simbaña-Rivera, Katherine, Gómez-Jaramillo, Ana María, Echeverría-Garcés, Gabriela, García-Cárdenas, Jennyfer M., Guevara-Ramírez, Patricia, Cabrera-Andrade, Alejandro, Puig San Andrés, Lourdes, Cevallos-Robalino, Doménica, Bautista, Jhommara, Armendáriz-Castillo, Isaac, Pérez-Villa, Andy, Abad-Sojos, Andrea, Ramos-Medina, María José, León-Sosa, Ariana, Abarca, Estefanía, Pérez-Meza, Álvaro A., Nieto-Jaramillo, Karol, Jácome, Andrea V., Morillo, Andrea, Arias-Erazo, Fernanda, Fuenmayor-González, Luis, Quiñones, Luis Abel, Kyriakidis, Nikolaos C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002106/
https://www.ncbi.nlm.nih.gov/pubmed/35422702
http://dx.doi.org/10.3389/fphar.2022.833174

Ejemplares similares

Ejemplares similares